Current Advances in Vasodilator Pharmacological Stress Perfusion Imaging

Seminars in Nuclear Medicine

Volumn 39, Issue 3, 2009, Pages 204-209

  Druz, Regina S ^a,b  

^a NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; AMINOPHYLLINE; CAFFEINE; DIPYRIDAMOLE; LEXISCAN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; REGADENOSON; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; ATRIOVENTRICULAR BLOCK; CLINICAL TRIAL; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG HALF LIFE; DRUG METABOLISM; DYSPNEA; FLUSHING; HEADACHE; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HEART VENTRICLE EXTRASYSTOLE; HEAT; HUMAN; ISCHEMIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SCINTIANGIOGRAPHY; SIDE EFFECT; ST SEGMENT DEPRESSION; STRESS PERFUSSION IMAGING; SUPRAVENTRICULAR PREMATURE BEAT; THORAX PAIN; TREATMENT CONTRAINDICATION;

ADENOSINE; ADULT; CORONARY ARTERY DISEASE; DIPYRIDAMOLE; EXERCISE TEST; FEMALE; HUMANS; MYOCARDIAL PERFUSION IMAGING; PURINES; PYRAZOLES; RADIOPHARMACEUTICALS; VASODILATOR AGENTS;

EID: 63049089857     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2008.12.003     Document Type: Review

References (19)

1. Astellas Pharma Internal Reports (2008), Astellas Pharma US, Deerfield, IL
2. Bokhari S., Ficaro E.P., and McCallister Jr. B.D. Adenosine stress protocols for myocardial perfusion imaging. J Nucl Cardiol 14 (2007) 415-416
3. Adenoscan (adenosine injection) package insert (2005), Astellas Pharma, US, Inc, Deerfield, IL
4. Henzlova M.J., Cerqueira M.D., Mahmarian J.J., et al. Stress protocols and tracers. J Nucl Cardiol 13 (2006) e80-e90
5. Klodas E., Miller T.D., Christian T.F., et al. Prognostic significance of ischemic electrocardiographic changes during vasodilator stress testing in patients with normal SPECT images. J Nucl Cardiol 10 (2003) 4-8
6. Kaufmann P.A. Differential effects of pharmacological stressors: More than meets the eye. J Nucl Cardiol 13 (2006) 311-312
7. Druz R.S., Akinboboye O.A., Grimson R., et al. Postischemic stunning after adenosine vasodilator stress. J Nucl Cardiol 11 (2004) 534-541
8. Hachamovitch R., Berman D.S., Kiat H., et al. Incremental prognostic value of adenosine stress myocardial perfusion single-photon emission computed tomography and impact on subsequent management in patients with or suspected of having myocardial ischemia. Am J Cardiol 80 (1997) 426-433
9. Hachamovitch R., Berman D.S., Shaw L.J., et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 97 (1998) 535-543
10. Gao Z., Li Z., Baker S.P., et al. Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists. J Pharmacol Exp Ther 298 (2001) 209-218
11. Lexiscan (regadenoson injection) package insert (2008), Astellas Pharma, US, Inc, Deerfield, IL
12. Cerqueira M.C., Nguyen P., et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective a2a agonist regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI Trial Results. JACC Cardiovascular Imaging 1 (2008) 307-316
13. Cerqueira M.D., Weissman N.J., Dilsizian V., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002) 539-542
14. Laighold S, Druz R: Initial clinical experience with a selective A2A receptor agonist, Regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nucl Cardiol (in press)
15. Gordi T., Blackburn B., and Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 47 (2007) 825-833
16. Mahmarian J.J., Shaw L.J., Filipchuk N.G., et al. A multinational study to establish the value of early adenosine technetium-99m sestamibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge after acute myocardial infarction. J Am Coll Cardiol 48 (2006) 2448-2457
17. Mahmarian J.J., Dakik H.A., Filipchuk N.G., et al. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. J Am Coll Cardiol 48 (2006) 2458-2467
18. Shaw L.J., Berman D.S., Maron D.J., et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 117 (2008) 1283-1291
19. Boden W.E., O'Rourke R.A., Teo K.K., et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356 (2007) 1503-1516